MannKind partners with Rose Pharma on inhaled rapid-acting GLP-1 weight-loss therapy

• MannKind entered a worldwide licensing and collaboration agreement with Rose Pharma to develop ROSE-010 Technosphere for weight management.
• Rose Pharma received exclusive rights to use MannKind’s Technosphere inhalation technology to develop and commercialize an inhaled rapid-acting GLP-1.
• MannKind will provide formulation, development, and manufacturing support through completion of a Phase 1b study in weight management.
• Consideration includes an equity stake in Rose Pharma and potential royalties on future net sales; financial terms were not disclosed.
• Rose Pharma will lead clinical development, regulatory strategy, and commercialization; MannKind will gain a board seat at Rose Pharma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090630PRIMZONEFULLFEED9823141) on September 09, 2026, and is solely responsible for the information contained therein.